<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809690</url>
  </required_header>
  <id_info>
    <org_study_id>4P-16-3</org_study_id>
    <secondary_id>NCI-2016-00814</secondary_id>
    <secondary_id>4P-16-3</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <secondary_id>R21EB017568</secondary_id>
    <nct_id>NCT02809690</nct_id>
  </id_info>
  <brief_title>18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer</brief_title>
  <official_title>Pilot Feasibility Study of 18F-FMAU PET for Diagnosing and Characterizing Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Biomedical Imaging and Bioengineering (NIBIB)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission&#xD;
      tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate&#xD;
      cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that&#xD;
      is given through the vein to take detailed pictures of areas inside the body where the tracer&#xD;
      is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the&#xD;
      disease has spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To perform a prospective clinical imaging evaluation of 18F-FMAU PET/CT in addition to&#xD;
      multiparametric magnetic resonance imaging (mpMRI) and standard transrectal ultrasound&#xD;
      (TRUS)-guided 12-core biopsy for detection and localization of primary tumor in 40 men with&#xD;
      suspected prostate cancer based on elevated/rising prostate specific antigen level, abnormal&#xD;
      digital rectal exam, or those with prior negative standard biopsy who are now returning for a&#xD;
      standard of care follow-up.&#xD;
&#xD;
      II. To examine the associations between the PET derived imaging parameters, serum PSA, mpMRI&#xD;
      parameters (apparent diffusion coefficient [ADC], Ktrans) and the biopsy histopathology&#xD;
      parameters.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive radiotracer F 18 d-FMAU intravenously (IV) over 1 minute and then undergo&#xD;
      18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and&#xD;
      standard of care transrectal ultrasound-guided biopsy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 24-96 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2016</start_date>
  <completion_date type="Anticipated">September 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of men for whom biopsy cores taken based only on the 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core or the mpMRI-directed prostate biopsies</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Standard descriptive methods will be used to summarize the data collected: means, standard deviations, ranges, and confidence intervals (or medians, quartiles), contingency tables, histograms, correlation coefficients (Pearson or Spearman) and scatter plots. The scatter plots and correlations between each of the histopathology parameters and the imaging parameters will be examined to better understand the relationships.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of men for whom the 18F-FMAU PET/CT identified all lesions that were found to have cancer based on the standard TRUS-guided and the mpMRI directed core prostate biopsies</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Standard descriptive methods will be used to summarize the data collected: means, standard deviations, ranges, and confidence intervals (or medians, quartiles), contingency tables, histograms, correlation coefficients (Pearson or Spearman) and scatter plots. The scatter plots and correlations between each of the histopathology parameters and the imaging parameters will be examined to better understand the relationships.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of men who completed both imaging procedures and for whom biopsy cores taken based only on the fluorine 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core prostate biopsies</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Standard descriptive methods will be used to summarize the data collected: means, standard deviations, ranges, and confidence intervals (or medians, quartiles), contingency tables, histograms, correlation coefficients (Pearson or Spearman) and scatter plots. The scatter plots and correlations between each of the histopathology parameters and the imaging parameters will be examined to better understand the relationships.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F-FMAU PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CAT</intervention_name>
    <description>Undergo 18F-FMAU PET/CT</description>
    <arm_group_label>Diagnostic (18F-FMAU PET/CT)</arm_group_label>
    <other_name>CAT Scan</other_name>
    <other_name>Computed Tomography</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FMAU</intervention_name>
    <description>Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT</description>
    <arm_group_label>Diagnostic (18F-FMAU PET/CT)</arm_group_label>
    <other_name>Fluorine F 18 d-FMAU</other_name>
    <other_name>2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (18F-FMAU PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multiparametric Magnetic Resonance Imaging</intervention_name>
    <description>Undergo mpMRI</description>
    <arm_group_label>Diagnostic (18F-FMAU PET/CT)</arm_group_label>
    <other_name>Multiparametric MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-FMAU PET/CT</description>
    <arm_group_label>Diagnostic (18F-FMAU PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Undergo TRUS-guided biopsy</description>
    <arm_group_label>Diagnostic (18F-FMAU PET/CT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled to undergo standard of care biopsy for suspected prostate cancer, or&#xD;
             re-biopsy with prior negative systemic biopsy or restaging biopsy in patients with&#xD;
             known prostate cancer on active surveillance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of myocardial infarction within 6 months of the enrollment&#xD;
&#xD;
          -  Active infection (except mild upper respiratory infections)&#xD;
&#xD;
          -  Active prostatitis&#xD;
&#xD;
          -  Non-prostate cancers currently on treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hossein Jadvar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjna Mani</last_name>
    <phone>323 442 7469</phone>
    <email>Sanjna.Mani@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjna Mani</last_name>
      <phone>323-442-7469</phone>
      <email>Sanjna.Mani@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Hossein Jadvar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

